Hydrocortisone acetate - Generic Drug Details

What are the generic drug sources for hydrocortisone acetate and what is the scope of freedom to operate?

Hydrocortisone acetate is the generic ingredient in nineteen branded drugs marketed by Viatris, Fougera Pharms, Able, Cenci, Imperium, Parke Davis, Purepac Pharm, Legacy Pharma, Sun Pharma Canada, Pharmacia And Upjohn, Pfizer, Bel Mar, Epic Pharma Llc, Watson Labs, Merck, Ingram Pharm, Fera Pharms, Colgate, X Gen Pharms, Monarch Pharms, Mylan Speciality Lp, Genus, and Ferndale Labs, and is included in forty NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for hydrocortisone acetate. Three suppliers are listed for this compound.

Summary for hydrocortisone acetate

US Patents:	0
Tradenames:	19
Applicants:	23
NDAs:	40
Drug Master File Entries:	14
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	21
Patent Applications:	7,103
Drug Prices:	Drug price trends for hydrocortisone acetate
What excipients (inactive ingredients) are in hydrocortisone acetate?	hydrocortisone acetate excipients list
DailyMed Link:	hydrocortisone acetate at DailyMed

See drug prices for hydrocortisone acetate

Recent Clinical Trials for hydrocortisone acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Merck Sharp & Dohme LLC	Phase 1
Orion Corporation, Orion Pharma	Phase 1
University Medical Center Groningen	Early Phase 1

See all hydrocortisone acetate clinical trials

Pharmacology for hydrocortisone acetate

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for hydrocortisone acetate

A01AC	Corticosteroids for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

A07EA	Corticosteroids acting locally
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

C05AA	Corticosteroids
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D07AA	Corticosteroids, weak (group I)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D07XA	Corticosteroids, weak, other combinations
D07X	CORTICOSTEROIDS, OTHER COMBINATIONS
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01CB	Corticosteroids/antiinfectives/mydriatics in combination
S01C	ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02BA	Corticosteroids
S02B	CORTICOSTEROIDS
S02	OTOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for hydrocortisone acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Speciality Lp	PROCTOFOAM HC	hydrocortisone acetate; pramoxine hydrochloride	AEROSOL, METERED;TOPICAL	086195-001	Approved Prior to Jan 1, 1982	BX	RX	Yes	Yes
Watson Labs	HYDROCORTISONE ACETATE	hydrocortisone acetate	INJECTABLE;INJECTION	085214-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ferndale Labs	PRAMOSONE	hydrocortisone acetate; pramoxine hydrochloride	LOTION;TOPICAL	083213-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Hydrocortisone Acetate: Market Dynamics and Financial Trajectory

Last updated: February 13, 2026

Hydrocortisone acetate is a synthetic corticosteroid used primarily for its anti-inflammatory and immunosuppressive properties. It is available as topical, injectable, and suppository formulations, with key applications in dermatology, endocrinology, and allergy treatments. The overall market for hydrocortisone acetate is shaped by patent life, generic competition, regulatory policies, and emerging biosimilar options.

---

Market Size and Growth Trends

The global corticosteroids market, inclusive of hydrocortisone acetate, was valued at approximately $5 billion in 2022. The segment-specific analysis shows hydrocortisone acetate as a dominant topical corticosteroid, with an estimated market share of 15-20% within corticosteroid formulations.

Historical Growth Data:

Year	Estimated Market Value (USD billion)	CAGR (2018-2022)	Drivers
2018	4.2	4.8%	Rising dermatological conditions
2019	4.4	4.8%	Increasing allergy prevalence
2020	4.6	4.3%	COVID-19 related dermatology needs
2021	4.8	4.3%	Expanded indications
2022	5.0	4.2%	Growing aging population

The projected CAGR from 2023 to 2028 remains approximately 4.0-4.5%, driven by demand in emerging markets and expanding uses.

---

Key Market Drivers

• Increased Prevalence of Dermatological Disorders: Conditions like eczema, psoriasis, and contact dermatitis promote sustained demand.
• Geriatric Population Expansion: Aging populations in North America, Europe, and Asia-Pacific increase corticosteroid prescriptions.
• Multiple Formulations: Availability in topical, injectable, and suppository forms broadens market penetration.
• Regulatory Environment: Generally favorable, with many formulations already approved. Penetration of generics is a significant factor.

Market Constraints

• Patent Expiry and Generic Competition: Many hydrocortisone acetate formulations are off-patent, leading to price erosion.
• Regulatory Scrutiny: Increased regulations on corticosteroid use, especially in pediatric populations, affect prescribing.
• Side Effect Profiles: Long-term or high-dose use is associated with adverse effects, which can impact demand.

---

Patent Landscape and R&D Trends

Most hydrocortisone acetate products are off-patent; patents related to specific formulations or delivery mechanisms (e.g., controlled-release patches) extend into the late 2020s. R&D efforts target novel delivery systems aimed at reducing side effects and enhancing bioavailability.

• Innovations:
  • Liposomal formulations to improve skin penetration.
  • Combination therapies with other anti-inflammatory agents.
  • Sustained-release formulations for longer efficacy.

Despite innovation, market entry barriers remain low due to the prevalence of generics, limiting premium pricing opportunities.

---

Financial Trajectory & Investment Outlook

Investment in hydrocortisone acetate manufacturing and R&D remains moderate, mainly driven by generic sales volume rather than high-margin innovations. Major pharmaceutical firms and generics manufacturers dominate the space.

Revenue Projections (2023-2028):

Year	Estimated Revenue (USD millions)	Notes
2023	950	Dominated by existing generics
2024	985	Slight market expansion, stable pricing
2025	1,020	Entry of biosimilars and innovative formulations
2026	1,055	Price competition intensifies
2027	1,090	Market saturation in mature regions
2028	1,130	Growth driven by emerging markets

The primary growth driver is the increasing adoption in Asia-Pacific, which accounts for approximately 35% of global sales by 2028, up from 28% in 2022.

---

Regulatory & Policy Environment

• FDA: Approves multiple over-the-counter and prescription formulations. Encourages biosimilar development.
• EMA: Similar regulatory stance with increased focus on biosimilars.
• India & China: Rapidly expanding markets with several local generics producers. Regulatory reforms aim to streamline approval processes.

Pricing pressures are expected to continue due to generic competition, with pricing declines averaging 3-5% annually post-patent expiration.

---

Competitive Landscape

Major players include:

• Pfizer: Offers branded hydrocortisone products, with extensive manufacturing capacity.
• Mylan (now part of Viatris): Large portfolio of generic corticosteroids.
• Sandoz: Focus on biosimilars and topical formulations.
• Market entry barriers are low; competition mainly on price and formulation innovation.

---

Key Takeaways

• The hydrocortisone acetate market is mature with moderate growth prospects.
• Patent expirations have introduced extensive generic competition, suppressing pricing.
• Growth hinges on emerging regional markets, formulation innovation, and biosimilars.
• Regulatory policies generally favor the continuation of availability but exert pressure on prices.
• R&D efforts are concentrated on delivery systems and reducing side effects rather than core molecule innovation.

---

FAQs

1. What factors influence the pricing of hydrocortisone acetate?
Market prices primarily depend on generic competition, regulatory approval status, formulation complexity, and regional reimbursement policies.

2. How does biosimilar development impact the hydrocortisone acetate market?
Biosimilars expand options and increase price competition, especially in mature markets, thereby reducing revenues for originators.

3. Which regions are expected to see the highest growth?
Asia-Pacific markets are projected to experience the highest growth, driven by increased healthcare access and rising dermatological conditions.

4. Are there new formulations in development?
Yes, research focuses on liposomal and controlled-release formulations to improve efficacy and reduce side effects.

5. How does the regulatory environment affect future market prospects?
Favorable approval pathways for biosimilars and generics facilitate market entry, but strict regulations on corticosteroid use can limit prescribing practices.

---

References

1. MarketsandMarkets, “Corticosteroids Market,” 2022.
2. Grand View Research, “Topical Corticosteroids Market Size, Share & Trends,” 2022.
3. US Food & Drug Administration, “Approved Drug Products,” 2023.
4. European Medicines Agency, “Medicinal Products in the European Union,” 2023.
5. IQVIA, “Global Trends in Dermatology and Corticosteroids,” 2022.